Table 4.RASSF1 methylation status and relative mRNA levels of RASSF1A in cervical SCC and cell lines.

n/n	TNM/ Clinical stage	Methylation status of promoter region*	mRNA level**, n-fold	Comments
Primary tumors
1	T2N0M0/II	U	2.6↑ (2.3↑ – 2.9↑)	Up-regulation
2	T2N0M0/II	U	1.0↓ (1.4↑ – 1.4↓)	Retention
3	T1N0M0/I	U	1.1↓ (1.4↑ – 1.5↓)
4	T1N0M0/I	U	1.2↓ (1.3↑ – 1.8↓)
5	T2N0M0/II	U	1.6↓ (1.4↓ – 1.8↓)
6	T2N1M0/III	U	1.7↓ (1.5↓ – 1.9↓)
7	T1N0M0/I	U	1.9↓ (1.4↓ – 2.6↓)
8	T1N0M0/I	U	2.2↓ (1.6↓ – 3.0↓)	Down-regulation
9	T2N0M0/II	U	2.8↓ (2.0↓ – 3.8↓)
10	T2N0M0/II	U	2.8↓ (2.0↓ – 3.9↓)
11	T2N0M0/II	U	3.9↓ (3.4↓ – 4.4↓)
12	T2N0M0/II	U	3.9↓ (3.7↓ – 4.2↓)
13	T1N0M0/I	U	4.5↓ (3.2↓ – 6.2↓)
14	T2N1M0/III	U	11↓ (10↓ – 13↓)
15	T1N1M0/III	U	13↓ (12↓ – 14↓)
16	T2N1M0/III	U	36↓ (29↓ – 45↓)
17	T2N1M0/III	U	74↓ (68↓ – 80↓)
Cell lines
18	SiHa	U	1.4↓ (1.1↓ - 1.7↓)	Retention
19	C4–1	U	4.5↓ (3.6↓ - 5.6↓)	Down-regulation
20	CaSki	U	8↓ (6↓ - 11↓)
21	C33A	Met	105↓ (67↓ - 162↓)

^**qPCR data, standard deviations of relative mRNA levels are shown in parentheses. Samples arranged according to RASSF1A levels of down-regulation. ↑, mRNA level increase; ↓, mRNA level decrease. *bisulfite sequencing data: Met,methylated; U, unmethylated.